

Just Us
2.2K posts

@Nightroads
I’d like to believe I leave this place a little less lonely, a little more just. - me. Immunology investor when I’m not fighting fascists.






Liking this News... $PRTG $3.86 Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer > finance.yahoo.com/news/portage-b…

$PRTG @PortageBiotech some very good news coming out today at #ASCO2023. #iNkt “Several target lesions were substantially reduced in size or completely resolved, and a majority of target lesions being clinically stable after twelve weeks,” said Dr. Ian Walters.

We’re pleased to share updated interim data on our lead #iNKT engager in a Phase 1/2 study for the treatment of #melanoma and #NSCLC at #ASCO23. For more details on the poster, click here: bit.ly/3qogjN0


$PRTG Ian walters CEO of portage is on this panel to discuss the next innovations in medicine and primarily the future of immuno-oncology (inkt ) right after there asco poster release on the 3rd June 😉 #ASCO23

@JacobPlieth $PRTG early stage in p1/p2 ,wont necessary see the press others receive,their abstract is worth a look Strong early efficacy results at low/mid dose in their inkt agonist treating nsclc stage 4. Patients had not repsonded to previous therapies and PD-1. meetings.asco.org/abstracts-pres…

$PRTG huge PR coming in the next week or so on early efficacy seen in their lead #inkt asset imm60. NSCLC 100% patients prior pd-1 No grade 3-5 19 lesions (2CR /10 SD /1 MR /6 PR All at low/ mid dose range Results be it early are up there with KEYTRUDA! $21bn pa drug! #ASCO23



$PRTG “well tolerated” “no MTD was determined” “2 lesions completely resolved” we can’t forget these patients have sadly been through several other treatments that failed. Well done @PortageBiotech you seem to be improving outcomes with PORT2 🙏 #ASCO23 #CancerResearch

$prtg CR in target lesions without establishing MTD. Patients have failed all other treatments so quite incredible early results seen #ASCO23



Check out this episode of @molecule2markt podcast, featuring our CEO Ian Walters! Ian discusses his background in the industry, along with Portage’s business model and progress in the clinic. Learn more about what makes Portage unique here: bit.ly/426vsA1



$PRTG Boom! Global trial site updated with June 5th start. This is running in parallel with the going p1/p2 uk arm of the trial. Data is coming ! And quick with 12 new trial locations in the US and spain. Merck collab is really kicking into action now $MRK

$PRTG Unlike other biotechs portage have designed import-201 trial to meet the exact clinical requirements $BMS & $MRK require. It helps when the chairman worked at BMS / brought nivolumab to market! ir.portagebiotech.com/news-releases/…